The third-tier compliance regulation 21 CFR Part 7 addresses what?

The third-tier compliance regulation 21 CFR Part 7 addresses what?

• A. Enforcement policy for drugs and medical devices
• B. Clinical trial protocols
• C. Labeling for devices
• D. Adverse event reporting

Answer: (A)

Enforcement policy for drugs and medical devices is what 21 CFR Part 7 addresses. This part lays out how the FDA approaches enforcement across regulated products, describing the range of actions the agency may take when requirements aren’t met and how it prioritizes and applies those actions. It’s about what the agency does when it finds noncompliance, rather than the specific substantive rules themselves. The other topics—clinical trial protocols, labeling requirements, and adverse event reporting—are governed by different regulations and sections, so Part 7 isn’t detailing those requirements but rather how enforcement flows in response to them.

Enforcement policy for drugs and medical devices is what 21 CFR Part 7 addresses. This part lays out how the FDA approaches enforcement across regulated products, describing the range of actions the agency may take when requirements aren’t met and how it prioritizes and applies those actions. It’s about what the agency does when it finds noncompliance, rather than the specific substantive rules themselves. The other topics—clinical trial protocols, labeling requirements, and adverse event reporting—are governed by different regulations and sections, so Part 7 isn’t detailing those requirements but rather how enforcement flows in response to them.